Innovate UK (IUK) Sustainable Medicines Manufacturing Innovation: Collaborative R&D

Funding Amount

Up to £7 million has been allocated to fund innovation projects in this competition.

A project’s total grant funding request must be between £500,000 and £1 million. No single organization in the consortium can claim more than 70% of the total project costs.

The intervention rate percentage that applicants can claim will depend on business size. For industrial research projects, applicants can claim:

Up to 70% of eligible project costs for micro or small organizations
Up to 60% for medium-sized organizations
Up to 50% for large organizations

For experimental development projects, applicants can claim:

Up to 45% of eligible project costs for micro or small organizations
Up to 35% for medium-sized organizations
Up to 25% for large organizations

Eligible Applicants

To lead a collaborative project, organizations must be a UK-registered:

Business of any size
Research and technology organization (RTO)
Catapult center
Not-for-profit organization
Public sector organization
Charity

The consortium must contain at least one UK-registered micro, small, or medium-sized enterprise (SME) claiming grant funding on this application.

To collaborate with the lead, your organization must be one of the following UK-registered:

Business of any size
Academic institution
Charity
Not-for-profit organization
Public sector organization
RTO
Catapult center

Eligible Activities

The aim of this competition is to drive innovation in sustainable medicines manufacturing across three key pillars:

Green chemistry
Circularity
Productivity and resource efficiency

These new manufacturing innovations are expected to support more environmentally sustainable manufacturing processes with significant and measurable improvements in at least one of the following areas:

Productivity
Waste reduction
Emissions reduction
Energy use reduction
Resource efficiency

Proposals must consider your commercial readiness levels (CRLs) and how this grant will enable progression in both technology readiness levels (TRLs) and CRLs towards a successful commercial end.